CBD Gummies for Inflammation: What the Research Shows
By PureCraft Editorial Team | PureCraft CBD | Updated October 2026
Inflammation is one of the most compelling applications for CBD — and one where the mechanistic evidence is among the strongest in the entire CBD research literature. Unlike some CBD applications where the evidence is largely self-report, CBD's anti-inflammatory action operates through multiple well-characterized molecular pathways that researchers have studied extensively in preclinical models and increasingly in human trials. The distinction that matters for consumers: acute inflammation (the redness and swelling from an injury or infection) serves a necessary protective function and shouldn't be fully suppressed. Chronic, systemic low-grade inflammation — the kind quietly running in the background of obesity, autoimmune conditions, metabolic syndrome, chronic pain, and aging — is where CBD's mechanisms are most relevant and least likely to interfere with necessary healing. This guide covers the biology, the evidence, and the practical applications with the detail the topic deserves.
The Two Types of Inflammation: Why the Distinction Matters
Acute Inflammation: Necessary and Protective
Acute inflammation is the immune system's first-responder cascade. When tissue is damaged — by injury, infection, or intense exercise — immune cells release cytokines (signaling proteins like TNF-α, IL-1β, and IL-6) that trigger vasodilation, increased vascular permeability, and recruitment of neutrophils and macrophages to clear debris and begin repair. This process is necessary. The redness, heat, swelling, and pain of acute inflammation are not pathological — they are the biology of healing. Aggressively suppressing acute inflammation (as some NSAIDs do at high doses) can actually impair recovery, delay tissue repair, and in the case of fractures, slow bone healing.
This matters for CBD users because CBD is not a pure acute anti-inflammatory in the way ibuprofen is. CBD does not primarily block COX-1/COX-2 enzymes (the prostaglandin pathway targeted by NSAIDs). Its mechanisms operate further upstream and through different pathways — which means it works differently from NSAIDs, may complement them, and is better suited to chronic inflammatory states than to acute injury-phase inflammation management.
Chronic Low-Grade Inflammation: The Silent Problem
Chronic low-grade inflammation is characterized by persistently elevated inflammatory markers — C-reactive protein (CRP), IL-6, TNF-α, IL-1β — without a specific acute trigger. It underlies or contributes to a remarkable range of conditions: cardiovascular disease, type 2 diabetes, metabolic syndrome, neurodegenerative disease, autoimmune conditions, chronic pain, obesity-associated inflammation, and the accelerated cellular aging associated with inflammaging. This type of inflammation persists because the resolution mechanisms are overwhelmed or disrupted — the immune system stays in a low-level activated state rather than completing the resolution phase after acute responses. CBD's mechanisms are particularly well-suited to chronic inflammatory states because they target resolution pathways and modulatory signaling rather than blunt suppression of the initial cascade.
CBD's Anti-Inflammatory Mechanisms: Five Distinct Pathways
1. CB2 Receptor / NF-κB Pathway Modulation
CB2 receptors are expressed primarily on immune cells — macrophages, neutrophils, T-cells, B-cells, dendritic cells, and microglial cells in the brain. Activation of CB2 receptors suppresses NF-κB (nuclear factor kappa B), the master transcription factor that drives the expression of pro-inflammatory genes. When NF-κB is activated, it upregulates production of TNF-α, IL-1β, IL-6, IL-8, and COX-2 — a cascade of pro-inflammatory signaling. CBD has CB2 receptor activity (indirect — via endocannabinoid tone and possibly as an inverse agonist at CB2 in some contexts) that helps suppress NF-κB-driven inflammatory gene expression. This is one of the most significant anti-inflammatory mechanisms in the entire CBD literature because NF-κB is the central hub of inflammatory signaling across most chronic inflammatory conditions.
2. PPARγ Activation and Inflammation Resolution
Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor involved in lipid metabolism, glucose homeostasis, and — critically — inflammation resolution. PPARγ activation suppresses inflammatory gene expression (including TNF-α and IL-6) and promotes the resolution phase of inflammation. CBD is a PPARγ agonist. This is the mechanism most relevant to metabolic inflammation — the low-grade inflammatory state associated with obesity, insulin resistance, and metabolic syndrome. PPARγ activation helps shift macrophages from a pro-inflammatory (M1) phenotype to an anti-inflammatory, tissue-repair (M2) phenotype, actively resolving inflammation rather than just suppressing it. CBD's PPARγ action may also contribute to neuroprotective effects by reducing neuroinflammation in the brain.
3. FAAH Inhibition and the Endocannabinoid Anti-Inflammatory Tone
CBD inhibits FAAH (fatty acid amide hydrolase), the enzyme that breaks down anandamide, the primary endogenous CB1 ligand. By reducing anandamide breakdown, CBD raises endocannabinoid tone. Beyond CB1's pain-modulating effects, endocannabinoids serve as immune modulators — they regulate cytokine production, immune cell migration, and the overall inflammatory balance through CB1 and CB2 receptors on immune cells. Healthy endocannabinoid tone supports immune regulation and helps prevent the chronic, unresolved inflammatory activation associated with endocannabinoid deficiency states. The endocannabinoid system can be thought of as an inflammatory rheostat — maintaining it at optimal tone (which CBD's FAAH inhibition supports) helps prevent the system from staying locked in pro-inflammatory mode.
4. Adenosine / ENT1 Anti-Inflammatory Effects
CBD's inhibition of ENT1 (equilibrative nucleoside transporter 1) increases extracellular adenosine concentrations. Adenosine, acting at A2A receptors on immune cells, is a potent anti-inflammatory signal — it suppresses TNF-α, IL-6, and other pro-inflammatory cytokines, and reduces neutrophil adhesion and tissue infiltration. The adenosine A2A pathway is one of the body's natural resolution mechanisms for inflammation — it rises during resolution phases to help turn off the inflammatory cascade. CBD's enhancement of adenosine signaling may therefore accelerate inflammatory resolution and contribute to suppression of chronic inflammatory states, particularly in tissues where adenosine-mediated immune regulation is active (including the gut, cardiovascular system, and CNS).
5. TRPV1 Desensitization and Neurogenic Inflammation
Neurogenic inflammation — inflammation driven by neuropeptide release from peripheral nerve endings — is mediated in part through TRPV1 (transient receptor potential vanilloid 1) channel activation. When TRPV1 is activated by pain stimuli, peripheral neurons release substance P and CGRP, which trigger local inflammatory responses in addition to pain signaling. CBD desensitizes TRPV1 channels over time — reducing their sensitivity to activation. This helps break the neuroinflammatory loop where pain signals drive further local inflammation, which drives more pain. For inflammatory pain conditions (arthritis, neuropathic pain, fibromyalgia), this TRPV1-mediated anti-neurogenic inflammation mechanism contributes to both the pain-relieving and anti-inflammatory effects simultaneously.
The Clinical Evidence: What Human Trials Show
Arthritis and Joint Inflammation
Arthritis represents the highest-volume clinical use case for cannabinoid anti-inflammatory applications. The preclinical evidence is robust: a landmark Philpott et al. (2017) study in rats with surgically-induced OA demonstrated that local CBD administration prevented the development of pain and nerve damage while reducing joint inflammation markers. In human survey data, Corroon and Phillips (2018) found arthritis/joint pain among the most commonly cited reasons for CBD use, with a high proportion of users reporting benefit — though self-report data without placebo control limits interpretation.
The important distinction for arthritis: osteoarthritis (OA) involves biomechanical joint degradation with secondary inflammation — CBD's anti-inflammatory mechanisms address the inflammatory component but not the structural damage. Rheumatoid arthritis (RA) is autoimmune — the immune system attacks joint tissue — and CBD's immune-modulatory CB2/NF-κB and PPARγ mechanisms are more mechanistically relevant, though RA is serious and managed with disease-modifying antirheumatic drugs (DMARDs) that should not be discontinued without rheumatologist guidance.
Inflammatory Bowel Conditions
The gut has the highest density of CB2 receptors in the body after the immune system. Inflammatory bowel conditions — Crohn's disease, ulcerative colitis, and non-specific IBD — involve dysregulated intestinal immune responses driving chronic gut inflammation. CBD's CB2/NF-κB suppression and PPARγ activation mechanisms have direct relevance in the gut lining. Several small pilot studies have examined CBD in IBD with mixed but promising results. CBD does not replace gastroenterologist-directed IBD treatment, but the mechanistic case for adjunct use is among the strongest in the CBD anti-inflammatory literature. The gut-specific note: oral CBD gummies, unlike topical applications, deliver the compound through the GI tract — meaning the gut wall itself is exposed to CBD before systemic absorption, potentially relevant for gut inflammatory conditions specifically.
Neuroinflammation and Brain Health
Neuroinflammation — activation of microglia (the brain's immune cells) and production of inflammatory cytokines in the CNS — underlies or contributes to neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and traumatic brain injury sequelae. It also contributes to the cognitive symptoms of depression, anxiety disorders, and post-viral syndromes. CBD crosses the blood-brain barrier and applies its CB2/NF-κB, PPARγ, and adenosine mechanisms directly to microglial cells. Russo (2016) and numerous preclinical studies have documented CBD's neuroprotective and neuroinflammatory suppression effects. Human trials in neuroinflammatory conditions are early-stage, but the preclinical mechanistic evidence is well-developed.
Post-Exercise Inflammation and Recovery
Exercise-induced muscle damage produces a necessary acute inflammatory response that drives adaptation — muscle protein synthesis, mitochondrial biogenesis, and strength gains require this inflammatory signal. Complete suppression of post-exercise inflammation (as with high-dose NSAIDs) can blunt adaptations. CBD's more modulatory profile — supporting resolution rather than blunt suppression — may be better suited to athletic recovery contexts than NSAIDs. The relevant mechanisms are TRPV1 desensitization reducing peripheral nociceptor sensitivity, CB2 modulation reducing excessive inflammatory signaling that extends into chronic soreness, and PPARγ supporting muscle macrophage polarization toward repair. See the CBD Gummies for Pain article for deeper athletic recovery coverage.
Inflammatory Condition Applicability: A Reference Guide
| Condition | Inflammation Type | Relevant CBD Mechanisms | Evidence Level |
|---|---|---|---|
| Osteoarthritis | Secondary joint inflammation | TRPV1, CB2/NF-κB, PPARγ | Moderate — strong preclinical; mixed human |
| Rheumatoid arthritis | Autoimmune systemic | CB2/NF-κB, PPARγ, immune modulation | Low human evidence; do not replace DMARDs |
| IBD (Crohn's/UC) | Gut mucosal immune | CB2/NF-κB (gut-high CB2), PPARγ, adenosine | Emerging — pilot studies, promising |
| Metabolic inflammation | Chronic low-grade systemic | PPARγ (strongest), CB2/NF-κB, FAAH | Preclinical strong; limited human trials |
| Neuroinflammation | Microglial CNS inflammation | CB2/NF-κB (microglia), PPARγ, adenosine A2A | Preclinical strong; human trials early |
| Post-exercise soreness | Acute exercise-induced | TRPV1, CB2 (resolution support), PPARγ | Moderate — survey and observational |
| Skin inflammation (acne, eczema) | Local/topical immune | CB2/NF-κB, TRPV1, sebocyte regulation | Best via topical; oral gummies indirect route |
CBD vs. NSAIDs for Inflammation: An Honest Comparison
| Factor | CBD Gummies | NSAIDs (ibuprofen/naproxen) |
|---|---|---|
| Primary mechanism | NF-κB, PPARγ, TRPV1, adenosine, FAAH | COX-1/COX-2 inhibition (prostaglandins) |
| Speed of acute effect | 30–90 min; builds over days/weeks | 30–60 min; acute single-dose effective |
| GI safety (daily use) | No GI ulcer or bleeding risk | Significant GI ulcer/bleeding risk with regular use |
| Cardiovascular risk | No established CV risk | Elevated CV risk with chronic use (especially COX-2 selective) |
| Renal effects | No established renal risk at consumer doses | Renal impairment risk with chronic/high-dose use |
| Acute injury inflammation | Less targeted for acute phase | More effective for acute phase pain/swelling |
| Chronic daily use safety | Better safety profile for long-term use | Increasing risk profile with chronic use |
| Drug interactions | CYP3A4/CYP2C19 — check with physician | Blood thinners, ACE inhibitors, diuretics — significant interactions |
Spectrum Choice for Inflammation: Does It Matter?
For inflammation, the spectrum choice has meaningful implications. Full-spectrum CBD contains trace THC (≤0.3%) alongside CBD and the full range of minor cannabinoids and terpenes. For chronic inflammatory conditions, the entourage effect has particular relevance:
Key Entourage Compounds for Inflammation
Beta-caryophyllene — A terpene and direct CB2 agonist. Beta-caryophyllene binds CB2 receptors directly, amplifying the CB2/NF-κB anti-inflammatory mechanism. This is arguably the most significant terpene for inflammation specifically, and it's present in full-spectrum and many broad-spectrum extracts. Its direct CB2 agonism adds a separate anti-inflammatory mechanism on top of CBD's effects.
CBG (cannabigerol) — Research suggests CBG has anti-inflammatory properties including NF-κB inhibition and potential PPARγ activity. Its combination with CBD may produce additive anti-inflammatory effects.
CBC (cannabichromene) — Shown in some research to reduce gut inflammation through TRPA1 and CB2 activity — potentially relevant for IBD contexts.
Myrcene and linalool — Terpenes with documented anti-inflammatory and analgesic properties in preclinical models, contributing to the whole-plant anti-inflammatory profile.
The Nano CBD Full Spectrum Berry Gummies provide the complete cannabinoid and terpene profile including trace THC, beta-caryophyllene, and minor cannabinoids — potentially the strongest anti-inflammatory option for those who can tolerate trace THC and are not subject to drug testing.
For those who require zero THC — drug testing, THC-sensitive individuals, or simple preference — the Nano CBD Broad Spectrum Gummies and Nano CBD Elderberry Broad Spectrum Gummies provide CBD plus minor cannabinoids and terpenes with THC removed to non-detectable levels. The elderberry variant adds elderberry's own documented anti-inflammatory and antioxidant properties (anthocyanins and quercetin) — a logical combination for immune and inflammatory applications. Both retain beta-caryophyllene and other relevant terpenes.
Oral vs. Topical CBD for Inflammation
Inflammation can be localized (a single joint, a patch of skin) or systemic (throughout the body). The delivery route matters:
Oral Gummies vs. Topical Cream: Choosing the Right Route
Oral gummies (like Nano CBD Broad Spectrum Gummies): produce systemic CBD distribution through circulation — reaching internal organs, the gut lining, the brain, and systemic immune cells. Best for systemic inflammation (metabolic, neuroinflammation, IBD, rheumatic conditions), and for conditions where inflammation is distributed throughout the body rather than localized. Also provides the full endocannabinoid, HPA, and sleep-improving mechanisms alongside the anti-inflammatory action.
Topical CBD cream (like Nano CBD Muscle and Joint Cream): concentrates CBD delivery in the specific area of application — the skin, underlying fascia, and peripheral nerve endings. Produces high local CBD concentrations without significant systemic absorption. Best for localized joint inflammation (a single arthritic knee, post-workout muscle soreness in a specific area), skin inflammation, and any case where precise anatomical targeting is more important than systemic coverage. Minimal drug interaction risk due to negligible systemic absorption.
Combination approach: For localized inflammatory pain (arthritic knee, sore lower back), oral gummies + topical cream applied directly to the affected area creates both systemic anti-inflammatory coverage and high local concentration at the pain source — addressing both the central and peripheral inflammatory components simultaneously.
Dosing Strategy for Inflammation
CBD Dosing Protocol for Inflammatory Conditions
Starting dose (Week 1–2): 15–20 mg once daily with food. A high-fat meal improves CBD bioavailability 3–5x — meaningful for anti-inflammatory dosing. Take at a consistent time each day for stable plasma levels.
Therapeutic range: Most anti-inflammatory applications require 20–40 mg daily for meaningful effect. The NF-κB and PPARγ mechanisms operate through gene expression changes that build over time with consistent dosing — not single-dose acute effects. Allow 4–6 weeks of consistent daily use before evaluating results.
Nanoemulsion advantage: PureCraft's nanoemulsion CBD (10–100 nm particle size, high-pressure homogenized) improves GI dispersion and absorption consistency compared to standard CBD oil — reducing the fed/fasted variability that makes standard oil dosing unpredictable. Nano CBD Broad Spectrum Softgels are convenient for consistent daily dosing at measured amounts.
Split dosing: For severe chronic inflammatory conditions, 20 mg morning + 20 mg evening provides more consistent plasma levels than a single 40 mg dose — supporting the ongoing CB2/NF-κB and PPARγ activity throughout the day.
Topical adjunct: For joint-specific inflammation, apply Nano CBD Muscle and Joint Cream directly to affected joints 2–3x daily alongside oral dosing — the dual route targets both peripheral and systemic inflammatory mechanisms.
Frequently Asked Questions
Do CBD gummies reduce inflammation, and how quickly do they work?
Research suggests CBD has anti-inflammatory properties through multiple well-characterized mechanisms — CB2/NF-κB suppression, PPARγ activation, FAAH/endocannabinoid tone enhancement, adenosine signaling, and TRPV1 desensitization. The timeline for experiencing effects has two phases. The acute phase: CBD reaches systemic circulation within 30–90 minutes (faster with PureCraft's nanoemulsion formulation), and some anti-inflammatory signaling activity may begin relatively quickly. The more significant phase for most inflammatory conditions is cumulative: the PPARγ and NF-κB mechanisms involve gene expression changes and macrophage phenotype shifts that take days to weeks to produce tissue-level changes. Most people using CBD for chronic inflammatory conditions report that meaningful symptom changes become noticeable over 2–6 weeks of consistent daily use rather than after a single dose. This is fundamentally different from an NSAID — CBD is better understood as a chronic inflammatory state modifier than as an acute anti-inflammatory. Set realistic expectations: if you're evaluating CBD for a chronic inflammatory condition, commit to 4–6 weeks of consistent daily use before assessing the results rather than stopping after a few doses because you didn't notice acute relief.
Can CBD gummies help with autoimmune inflammation?
Autoimmune conditions — where the immune system attacks the body's own tissues — represent some of the most complex and serious inflammatory states, and honesty is essential here. CBD has immune-modulatory properties through CB2 receptors on T-cells, B-cells, dendritic cells, and macrophages. In preclinical autoimmune models, CBD has shown effects including reduction of inflammatory cytokines, modulation of T-cell activity, and attenuation of autoimmune progression. The CB2/NF-κB pathway in particular is relevant because NF-κB drives the expression of inflammatory cytokines that mediate tissue damage in autoimmune conditions like RA, lupus, and psoriasis. However: autoimmune conditions are managed with established disease-modifying treatments (DMARDs, biologics, corticosteroids) that fundamentally alter disease progression. CBD is not an established autoimmune disease modifier and should not replace these treatments. Where CBD may add value is as an adjunct — reducing the inflammatory symptom burden alongside prescribed treatment, potentially contributing to better sleep and reduced stress (both of which independently affect autoimmune disease activity). Anyone with a diagnosed autoimmune condition should discuss CBD supplementation with their rheumatologist or immunologist, particularly given CBD's CYP enzyme interactions with medications commonly used in autoimmune treatment.
What dose of CBD gummies is needed for anti-inflammatory effects?
The honest answer is that the therapeutic dose for anti-inflammatory effects in humans is not precisely established — human dose-finding trials specifically for inflammation are limited. Based on the preclinical mechanistic data and the available human evidence, most practitioners working with CBD for inflammatory conditions suggest a range of 20–40 mg per day for chronic inflammatory applications. This is higher than anxiety dosing (10–20 mg) because the relevant mechanisms — PPARγ gene expression changes, NF-κB suppression at the tissue level — likely require more sustained and higher plasma concentrations than the relatively rapid-acting serotonergic pathways for anxiety. The fat-meal absorption interaction is particularly relevant for anti-inflammatory dosing: CBD bioavailability is 3–5x higher after a high-fat meal compared to fasting. Taking your CBD gummy with a meal containing healthy fats (avocado, olive oil, nuts) is a meaningful practical optimization. Start at 15–20 mg daily with food for the first two weeks, then increase to 25–40 mg if you're not experiencing the desired results. The Nano CBD Broad Spectrum Gummies and Nano CBD Full Spectrum Berry Gummies are well-suited to dose titration for inflammatory applications.
Can CBD gummies help with gut inflammation or IBS?
The gut is an interesting case for oral CBD specifically because, unlike most organ systems, it is directly exposed to CBD at relatively high concentrations as the gummy is absorbed through the GI tract — before significant first-pass hepatic metabolism occurs. The intestinal lining has among the highest CB2 receptor density in the body, making it a particularly relevant target for CBD's CB2/NF-κB anti-inflammatory mechanisms. Some research suggests CBD also affects gut motility, gut-brain axis signaling, and intestinal permeability ("leaky gut") in ways that may be relevant for functional gut conditions. For IBD (Crohn's disease, ulcerative colitis) specifically — a serious autoimmune gut condition — several pilot studies have examined CBD with mixed but intriguing results, though it should not replace gastroenterologist-directed treatment. For IBS (irritable bowel syndrome), which is a functional condition rather than a purely inflammatory one, the endocannabinoid system's role in gut motility and gut-brain signaling provides a different rationale — more about normalizing gut function than suppressing immune-driven inflammation. The Nano CBD Broad Spectrum Softgels offer consistent daily oral dosing relevant to gut inflammatory applications.
Is full-spectrum or broad-spectrum CBD better for inflammation?
For inflammation specifically, full-spectrum CBD has a meaningful mechanistic advantage over isolate and arguably over broad-spectrum, due to beta-caryophyllene. Beta-caryophyllene is a terpene present in hemp that is also a direct CB2 agonist — meaning it binds and activates CB2 receptors through a different mechanism than CBD. Since CB2/NF-κB suppression is one of the primary anti-inflammatory pathways, having a direct CB2 agonist (beta-caryophyllene) alongside an indirect CB2 modulator (CBD) creates additive anti-inflammatory signaling at the immune cell level. Full-spectrum extracts contain beta-caryophyllene, CBG, CBC, and trace THC — all of which contribute to the anti-inflammatory profile through the entourage effect. The Nano CBD Full Spectrum Berry Gummies provide this complete profile. For those who cannot use full-spectrum due to drug testing or THC sensitivity, well-formulated broad-spectrum extracts retain beta-caryophyllene and most minor cannabinoids — the Nano CBD Broad Spectrum Gummies and Nano CBD Elderberry Broad Spectrum Gummies are strong options. CBD isolate — pure CBD without terpenes or minor cannabinoids — lacks the beta-caryophyllene CB2 synergy and is the least preferred formulation for anti-inflammatory applications where the entourage effect matters most.
Can CBD gummies be taken with anti-inflammatory medications?
This is an important safety question with a nuanced answer. CBD inhibits CYP3A4 and CYP2C19 enzymes — the same liver enzymes that metabolize many medications. For NSAIDs (ibuprofen, naproxen): these are primarily metabolized by CYP2C9, with some CYP3A4 involvement. CBD may moderately increase NSAID plasma levels, but the interaction is generally considered low risk at consumer CBD doses. More significant: corticosteroids (prednisone, dexamethasone) used for inflammatory conditions are CYP3A4 substrates — CBD may increase their plasma concentrations, potentially amplifying both their therapeutic effects and side effects. Methotrexate (common DMARD for RA and psoriasis) is renally excreted rather than CYP-metabolized, so the interaction risk is lower. Biologics (TNF-α inhibitors like adalimumab, etanercept) are biological proteins metabolized differently — CYP interaction is not the concern, but their profound immune-suppressing effects alongside CBD's immune-modulatory effects should be reviewed with a rheumatologist. The most conservative approach: inform your physician and pharmacist about CBD supplementation if you're taking any prescription anti-inflammatory or immunosuppressive medication. For over-the-counter NSAIDs taken occasionally, the risk at moderate CBD doses is low. For chronic use of prescription anti-inflammatory drugs, a physician check is the right protocol.
Related Articles
- → CBD Gummies for Pain: What the Research Actually Shows
- → CBD Gummies for Anxiety: What the Research Actually Shows
- → CBD Gummies for Stress Relief: What the Research Shows
- → CBD Gummies for Sleep: What the Research Actually Shows
- → How Long Do CBD Gummies Take to Work?
References
- Blessing EM, et al. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12(4):825–836. PMID: 26341731
- Shannon S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18–041. PMID: 30624194
- Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2016;4(1):245–259. PMID: 28861491
- Crippa JA, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder. J Psychopharmacol. 2011;25(1):121–130. PMID: 20829306
- Corroon J, Phillips JA. A Cross-Sectional Study of Cannabidiol Users. Cannabis Cannabinoid Res. 2018;3(1):152–161. PMID: 30014049
- Capano A, et al. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients. Postgrad Med. 2020;132(1):56–61. PMID: 31711352
Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. CBD gummies are dietary supplements; these statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease or medical condition, including any inflammatory, autoimmune, or chronic pain condition. Chronic inflammatory conditions should be evaluated and managed by a qualified healthcare provider. Do not discontinue prescribed anti-inflammatory, immunosuppressive, or disease-modifying medications without physician guidance. CBD may interact with prescription medications through CYP enzyme pathways — consult your physician or pharmacist before using CBD alongside any prescription medication.
